Foundayo oral GLP-1 pill approved in UK, could cut injection use
The UK regulator approved Foundayo (orforglipron), a daily oral GLP-1 pill for weight management and type 2 diabetes, joining FDA-approved status earlier in 2026. Trials show weight loss and HbA1c reductions, with simpler dosing than injectable GLP-1 drugs.
Key takeaways
- The UK MHRA approved Foundayo (orforglipron) as a daily oral GLP-1 treatment for weight management and type 2 diabetes.
- This makes the UK the first country in Europe to authorize the tablet form for these indications, with FDA approval also granted earlier in 2026 for weight management.
- ATTAIN-2 trial involved 1,613 adults over 72 weeks to evaluate efficacy and safety of orforglipron against placebo.
- Foundayo’s dosing is designed to be simpler and less restricted by meals and timing than some oral GLP-1 competitors.
- Regulators will continue post-market monitoring to assess ongoing safety and effectiveness.
What Happened
The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom authorised Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist, for use in weight management and type 2 diabetes. The approval makes the UK the first country in Europe to authorize the tablet form, and follows an FDA approval earlier in 2026 that covered weight management in adults with obesity or related conditions.
The decision was based on an assessment of safety, quality, and effectiveness, with ongoing monitoring of Foundayo’s safety and effectiveness as with other GLP-1 therapies. The tablet is approved to be used alongside a reduced-calorie diet and increased physical activity in eligible adults. UK labeling specifies eligibility includes adults with BMI 30+ or BMI 27–30 with a weight-related condition, and it also targets improving blood sugar control in adults with type 2 diabetes.
In Europe, Foundayo joins other GLP-1 therapies that have oral forms, but its UK approval expands to cover both weight management and type 2 diabetes, whereas the FDA’s approval in the United States covered weight management alone. The broader UK indication reflects the agency’s assessment and labeling decisions as of August 2026.
Evidence from the pivotal ATTAIN-2 phase 3 trial, conducted in 1,613 adults with overweight or obesity and type 2 diabetes, underpins these approvals. Participants received various doses of orforglipron or placebo for 72 weeks, alongside lifestyle modifications.
Why It Matters
Oral GLP-1 options could reduce patients’ reliance on injectable therapies, addressing administration barriers that limit adherence. The oral formulation, being a non-peptide small molecule, is described by researchers as having advantages in dosing flexibility and manufacturing, potentially lowering distribution costs compared with peptide-based oral GLP-1 drugs. If the efficacy and safety seen in trials translate to real-world use, Foundayo could shift weight-management and diabetes care paradigms by expanding access to GLP-1 therapy without injections.
Background
GLP-1 receptor agonists began as diabetes treatments and have expanded to obesity management. Oral formulations exist, but not all have the same dosing convenience or efficacy. Foundayo’s development emphasizes daily administration with fewer food and water restrictions compared to some alternatives, aiming to improve patient experience and adherence.
Key Facts
- MHRA licensed Foundayo (orforglipron) in the UK for weight management and type 2 diabetes on August 10, 2026.
- The UK is the first European country to authorize the tablet form for both indications.
- FDA approved orforglipron for chronic weight management in adults earlier in 2026; UK labeling includes type 2 diabetes in addition to weight management.
- ATTAIN-2 phase 3 trial involved 1,613 adults with overweight/obesity and type 2 diabetes, assessing 72-week outcomes with orforglipron vs placebo plus lifestyle changes.
- Foundayo is described as a once-daily non-peptide small-molecule GLP-1 receptor agonist, with dosing that can be taken with or without food and without strict timing after meals.
What Happens Next
Regulators will continue post-market surveillance of Foundayo in the UK, including safety and effectiveness monitoring. Clinicians will incorporate the new tablet option into treatment plans for adults meeting BMI and diabetes criteria, alongside lifestyle interventions. Further data may clarify long-term outcomes and comparative effectiveness versus injectable GLP-1 therapies.
Sources reviewed
Project Chintan independently synthesized and analyzed information cross-checked across the sources listed above.
Related stories
Tukaram Mundhe leads FDA raids reshaping Mumbai’s food scene
US FDA Issues Warning Letter to Aurobindo Pharma's Eugia Pharma Unit
India FDA Takes Action Against Domino's and Other Food Establishments
